S-1 - Onconetix, Inc. (0001782107) (Filer)

PRE 14A - Onconetix, Inc. (0001782107) (Filer)

8-K - Onconetix, Inc. (0001782107) (Filer)

8-K - Onconetix, Inc. (0001782107) (Filer)

S-8 - Onconetix, Inc. (0001782107) (Filer)

8-K - Onconetix, Inc. (0001782107) (Filer)

8-K - Onconetix, Inc. (0001782107) (Filer)

8-K - Onconetix, Inc. (0001782107) (Filer)

8-K - Onconetix, Inc. (0001782107) (Filer)

8-K/A - Onconetix, Inc. (0001782107) (Filer)

3 - Onconetix, Inc. (0001782107) (Issuer)

3 - Onconetix, Inc. (0001782107) (Issuer)

3 - Onconetix, Inc. (0001782107) (Issuer)

3 - Onconetix, Inc. (0001782107) (Issuer)

3 - Blue Water Biotech, Inc. (0001782107) (Issuer)

3 - Blue Water Biotech, Inc. (0001782107) (Issuer)

4 - Blue Water Biotech, Inc. (0001782107) (Issuer)

4 - Blue Water Biotech, Inc. (0001782107) (Issuer)

4 - Blue Water Biotech, Inc. (0001782107) (Issuer)

4 - Blue Water Biotech, Inc. (0001782107) (Issuer)

CINCINNATI, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV) ("BWB" or the "Company") today announced the acquisition of Proteomedix AG, a private, commercial-stage diagnostics oncology company (the "Transaction"), and introduced a new name for the combined Company: Onconetix, Inc. The Transaction reflects a transformation of the business to one focused on the research, development and commercialization of proprietary science and technologies for therapeutics, diagnostics and services for the treatment of cancer. The acquisition of Proteomedix for all stock consideration provides its shareholders with an initial 19.9% ownership stake of Onconetix. With the tran

CINCINNATI, May 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. ("Blue Water" or the "Company"), a biotechnology company spanning multiple sectors, today announced its financial results for the quarter ended March 31, 2023 and provided an update on recent business developments and Company progress. Blue Water Biotech is a biological and pharmaceutical technology company developing multiple preclinical vaccine candidates across various infectious diseases and owns the FDA-approved benign hyperplasia ("BPH") asset, ENTADFI®. "Blue Water's recent growth is highlighted by our acquisition of ENTADFI®, as well as our subsequent rebranding initiative and name change to reflect our transiti

Acquisition Transforms the Company into a Broader Pharmaceutical Company Spanning Multiple Sectors Company Announces Corporate Name Change to Underscore Broader Focus Company to Host a Conference call Today, April 20th, at 8:30am EDT to Discuss Asset Purchase and Company Transformation CINCINNATI, April 20, 2023 (GLOBE NEWSWIRE) --  Blue Water Vaccines Inc. ("BWV" or "Blue Water" or the "Company"), today announced the signing of an Asset Purchase Agreement (the "Agreement") with Veru Inc. ("Veru") for the purchase of ENTADFI®, an FDA-approved treatment for benign prostatic hyperplasia ("BPH") that counteracts negative sexual side effects seen in men on alternative BPH therapies. Unde

Closed private placement in April 2022, with net proceeds of approximately $6.9 millionSigned multiple strategic agreements and collaborations to further vaccine candidate research, development, and manufacturing$22.2 million in cash as of June 30, 2022 CINCINNATI, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or "the Company") today announced its financial results for the second quarter ended June 30, 2022 and provided an update on recent business developments and progress. Blue Water Vaccines is a pre-clinical stage biotechnology company developing vaccines against multiple infectious diseases, including acute otitis media (AOM) from Streptoc

CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (NASDAQ:BWV) ("Onconetix" or the "Company") today issued the following shareholder letter from the Company's Chief Executive Officer, Dr. Neil Campbell. To Our Valued Shareholders, As 2023 draws to a close, I am eager to share with you the significant strides Onconetix, Inc. (formerly Blue Water Biotech, Inc.) has made in our journey towards becoming a leader in oncology. This past quarter has been transformative, marked by strategic shifts and notable achievements, all aimed at enhancing the value we bring to you as our shareholders. To reflect our recent achievements and renewed oncology focus, we have rebranded as Onconet

CINCINNATI, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV) ("BWB" or the "Company") today announced the acquisition of Proteomedix AG, a private, commercial-stage diagnostics oncology company (the "Transaction"), and introduced a new name for the combined Company: Onconetix, Inc. The Transaction reflects a transformation of the business to one focused on the research, development and commercialization of proprietary science and technologies for therapeutics, diagnostics and services for the treatment of cancer. The acquisition of Proteomedix for all stock consideration provides its shareholders with an initial 19.9% ownership stake of Onconetix. With the tran

CINCINNATI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV) ("BWB" or the "Company"), today announced the execution of a non-binding term sheet regarding the acquisition of a private commercial stage oncology biotechnology company (the "Proposed Transaction"). This latest announcement is part of the Company's new business strategy focusing on oncology. The Company plans to commercialize therapeutics, diagnostics and clinician services, which will serve as the foundation for the Company's future operations. The Proposed Transaction furthers a shift in business strategy driven by BWB's decision to align with both the market value drivers provided by its new oncolog

CINCINNATI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV) ("BWB" or the "Company") today announced that it has received a letter from the Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the Nasdaq Stock Market, LLC Listing Rule 5250(c)(1) (the "Rule"). The Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (SEC). On October 20, 2023, BWB filed its Form 10-Q for the period ended June 30, 2023, and thus is now current on its SEC financial reporting obligations. About Blue Water Biotech, Inc. Blue Water Biotech, Inc. is a commercial stage biotec

CINCINNATI, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV) ("BWB" or the "Company") today issued the following shareholder letter from the Company's Chief Executive Officer Dr. Neil Campbell. Dear Shareholders, As we close out October and the first month under my tenure, I want to take this opportunity to personally communicate with you while providing an update on the direction of Blue Water Biotech. 2023 has been an eventful year that has significantly influenced the Company's progression in generating shareholder value. On October 24, 2023, Blue Water Biotech received a letter from Nasdaq informing the Company that it is back in compliance w

CINCINNATI, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV), which is focused on developing and commercializing transformational therapies to address significant global health challenges, today announced the appointments of Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO, effective immediately. Dr. Campbell has also joined the Company's board of directors. Dr. Campbell has more than 35 years of experience with public and private companies focused on biopharmaceuticals, health technologies, nanotechnologies, artificial intelligence and super-computing. He has held leadership positions with IGEN International, now Roche; Celera Genomics; and Abbott

CINCINNATI, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. ("Blue Water" or the "Company"), a biotechnology and pharmaceutical company spanning multiple sectors, today announced that it received a delinquency notification letter ("Notice") from the Listing Qualifications staff of the Nasdaq Stock Market LLC ("Nasdaq") on August 22, 2023 due to the Company's non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023 (the "Form 10-Q"). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securi

CINCINNATI, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. ("Blue Water" or the "Company"), a biotechnology and pharmaceutical company spanning multiple sectors, today announced the signing of an agreement with Copay Consultants, LLC ("Copay Consultants") to build copay assistance programs for Blue Water's commercial products, including ENTADFI®, which was acquired in April and ZONTIVITY®, which is expected to be acquired in the coming weeks after the signing of an asset purchase agreement in June. Copay Consultants team has over 40 years of combined experience in the life science industry, including creation of manufacturer sponsored patient savings programs, pharmacy adjudic

CINCINNATI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. ("Blue Water" or the "Company") (NASDAQ:BWV), today announced the closing of its previously announced exercise of certain existing warrants to purchase 2,486,214 shares of its common stock at a reduced exercise price of $1.09 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants were approximately $2.7 million, before deducting placement agent fees and other offering expenses payable by the Company. H.C. Wainwright acted as the exclusive placement agent for this transaction. The Company expects to use the net proceeds from the transaction fo

CINCINNATI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. ("Blue Water" or the "Company") (NASDAQ:BWV), today announced it has entered into a definitive agreement for the exercise of certain existing warrants to purchase 2,486,214 shares of its common stock at a reduced exercise price of $1.09 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $2.7 million, before deducting placement agent fees and other offering expenses payable by the Company. The transaction is expected to close on or about August 2, 2023, subject to satisfaction of customary closing condition

CINCINNATI, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV), which is focused on developing and commercializing transformational therapies to address significant global health challenges, today announced the appointments of Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO, effective immediately. Dr. Campbell has also joined the Company's board of directors. Dr. Campbell has more than 35 years of experience with public and private companies focused on biopharmaceuticals, health technologies, nanotechnologies, artificial intelligence and super-computing. He has held leadership positions with IGEN International, now Roche; Celera Genomics; and Abbott

CINCINNATI, April 26, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. ("Blue Water" or the "Company"), a biotechnology company spanning multiple sectors, today announced the appointment of Jay Newmark, M.D., MBA as the Company's Chief Medical Officer. Dr. Newmark is a board-certified urologist with over 30 years of experience managing Men's Health issues, including benign prostatic hyperplasia ("BPH"). Blue Water currently owns ENTADFI®, an FDA-approved treatment for BPH that counteracts negative sexual side effects seen in men on alternative BPH therapies. Dr. Newmark's appointment will support Blue Water's upcoming launch of ENTADFI® and he will work closely with Blue Water management

CINCINNATI, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or the "Company"), today announced the appointment of Frank Jaeger, seasoned commercial operations and business development executive, as Senior Vice President of Marketing and Business Development. Mr. Jaeger brings over 25 years of biopharmaceutical experience to the BWV team, from start-up to large global pharma with significant pre-launch, launch, and in-market commercialization experience. His background in R&D, Medical Affairs, Business Development, and throughout Commercial Operations provides a broad world view and an understanding of varying perspectives. Mr. Jaeger has a wide r

CINCINNATI, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or the "Company"), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the appointment of Timothy Ramdeen, seasoned public market and private equity investment leader, to its board of directors. Mr. Ramdeen has nearly a decade of experience in private equity and hedge fund investing, capital markets, and company formation. Since June 2022, Mr. Ramdeen has been founder and managing partner of Dharma Capital Advisors, an investment and advisory firm focused on early-stage private and public companies. From March

CINCINNATI, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or the "Company"), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the appointment of seasoned advisor and executive, Vuk Jeremić, to the Company's board of directors. Mr. Jeremić brings decades of experience in operational and strategy advisement on a global scale for both private and public companies. Currently, Mr. Jeremić is the President of the Center for International Relations and Sustainable Development (CIRSD), a global public policy think-tank, and Editor-in-Chief of the quarterly magazine "Horizo

CINCINNATI, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or "the Company"), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the appointment of Simon Tarsh, seasoned financial consultant with experience in the life science industry, to its board of directors at BWV's annual meeting. Mr. Tarsh brings over 40 years of experience in the financial industry to the Company, most recently serving global clients as a Senior Managing Director in the Finance and Enterprise Performance Practice at Deloitte Consulting since 2007. He led a growing global practice focused on Op

Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Kimberly M. Murphy, member of the Board of Directors, as President and Chief Executive Officer effective June 23, 2022. Ms. Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the successful US and Global launch of Merck's HPV/Gardasil Franchise. Ms. Murphy joined Oragenics' Board of Directors in 2020. "As a Board Member, Ms. Murphy's extensive experience in the vaccine industry has provided valuable insight for Oragenics' corporat

SC 13G/A - Onconetix, Inc. (0001782107) (Subject)

SC 13G/A - Onconetix, Inc. (0001782107) (Subject)

SC 13G - Onconetix, Inc. (0001782107) (Subject)

SC 13D - Blue Water Biotech, Inc. (0001782107) (Subject)

SC 13D - Blue Water Vaccines Inc. (0001782107) (Subject)

SC 13G - Blue Water Vaccines Inc. (0001782107) (Subject)

SC 13G - Blue Water Vaccines Inc. (0001782107) (Subject)

SC 13G - Blue Water Vaccines Inc. (0001782107) (Subject)

SC 13D - Blue Water Vaccines Inc. (0001782107) (Subject)

SC 13D - Blue Water Vaccines Inc. (0001782107) (Subject)